Related Experiment Videos
Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates
A-J Carrillo-Muñoz1, S Brió, R Alonso
1Dept. Microbiología, ACIA, P.O. Box 10178, E-08080 Barcelona, Spain. acarrillo17@terra.es
Abstract:
The in vitro susceptibility of 225 clinical isolates of yeasts to ciclopiroxolamine (CPO) was compared with that of clotrimazole, econazole, ketoconazole, miconazole, tioconazole, fluconazole, itraconazole and nystatin using a standardized agar diffusion method (NeoSensitabs). Two hundred and eight strains of yeasts comprising 16 species of Candida and 22 strains belonging to other yeast genera were tested. One strain (0.4%) was resistant, four strains (1.8%) of intermediate susceptibility and 220 strains (97.3%) susceptible to CPO. More strains were susceptible to CPO than to the other antifungals studied. Susceptibility patterns of antifungal agents were not linked to species. The in vitro antifungal susceptibility profile of CPO was better than topical azole derivatives or fluconazole and itraconazole against a wide variety of clinically important yeasts.
Insights
Ciclopiroxolamine (CPO) demonstrates superior in vitro antifungal activity against clinical yeast isolates compared to other common antifungals. This study highlights CPO
Area of Science:
- Mycology
- Antimicrobial Susceptibility Testing
- Dermatology
Background:
- Yeast infections pose a significant clinical challenge, necessitating effective antifungal agents.
- Existing antifungal therapies have varying efficacy and resistance patterns.
- Ciclopiroxolamine (CPO) is a topical antifungal agent with a broad spectrum of activity.
Purpose of the Study:
- To evaluate the in vitro antifungal susceptibility of clinical yeast isolates to ciclopiroxolamine (CPO).
- To compare the efficacy of CPO against established antifungal drugs, including azole derivatives and nystatin.
- To determine if susceptibility patterns are species-specific.
Main Methods:
- A standardized agar diffusion method (NeoSensitabs) was employed.
- 225 clinical yeast isolates were tested, including 16 Candida species and other genera.
- Susceptibility to CPO and nine other antifungal agents was assessed.
Main Results:
- 97.3% of yeast isolates were susceptible to CPO, with only one resistant strain.
- CPO exhibited broader susceptibility among tested yeasts compared to clotrimazole, econazole, ketoconazole, miconazole, tioconazole, fluconazole, itraconazole, and nystatin.
- Antifungal susceptibility patterns were not significantly linked to specific yeast species.
Conclusions:
- Ciclopiroxolamine (CPO) shows excellent in vitro activity against a wide range of clinical yeast isolates.
- CPO's susceptibility profile is superior to topical azoles, fluconazole, and itraconazole in this study.
- CPO represents a promising therapeutic option for superficial fungal infections caused by yeasts.